PM360 2020 Trailblazer Awards Consumer Website/Online Initiative Winner Sanofi Genzyme, Regeneron Pharmaceuticals, and MicroMass Communications, Inc.

Atopic Dermatitis Web Experience (Sanofi Genzyme, Regeneron Pharmaceuticals, MicroMass Communications, Inc.)

The CRM branded web experience for DUPIXENT is designed to meet the unique needs of adults and their caregivers as well as caregivers of teens. This website is for registrants and users who opted-in to receive communications including emails to drive to specific and relevant content.

During a deep-dive research initiative by MicroMass Communications, Inc., it became apparent that the preferred branded CRM web experience for DUPIXENT should deliver content in a way that is informative, but also digestible. To that end, this experience is designed to meet the unique needs of adults and caregivers of teens. It provides education and skill-building opportunities and includes an evidence-based behavioral approach to help overcome barriers to treatment, build motivation and skills to stay on track, and optimize communication.

The goal of the new interactive site was to create a user experience for patients and caregivers who are considering or taking DUPIXENT and to consider what may be possible with a change in treatment and mindset. The site helps both those considering and those taking the treatment develop a care routine, gain comfort with injections, and learn how to transform negative thoughts into positive ones. The web experience keeps the patient and caregiver engaged and informed while driving engagement to DUPIXENT.

Ads

You May Also Like

PM360 2023 Trailblazer Awards Advertising Agency or Supplier/Vendor CEO of the Year Ken Begasse Jr.

Ken Begasse Jr., Founder and CEO, ConcentricLife Throughout his leadership career, Ken Begasse Jr. ...

2018 Pharma Choice DTC/DTP Silver Winner The Bloc and Novartis

The Bloc Novartis PROMACTA Pediatric Starter Kit This pediatric patient starter kit gives patients ...

2016 Trailblazers Award Winners

On Friday, September 23rd, the life sciences industry was treated to one hell of ...